Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
ClinicalTrials.gov study NCT03125902. IPD Sharing: Not stated. Countries: 24. Publications: 1.
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03853707. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
ClinicalTrials.gov study NCT03044730. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT03371017. IPD Sharing: Not stated. Countries: 28. Publications: 0.
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT00479674. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
ClinicalTrials.gov study NCT03256344. IPD Sharing: YES. Countries: 6. Publications: 1.
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT02445391. IPD Sharing: YES. Countries: 2. Publications: 2.
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
ClinicalTrials.gov study NCT02595905. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
ClinicalTrials.gov study NCT03483012. IPD Sharing: NO. Countries: 1. Publications: 0.
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04758780. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01889238. IPD Sharing: YES. Countries: 7. Publications: 2.
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02301988. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
ClinicalTrials.gov study NCT02876302. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: Investigating the combined effects of jadomycin B and celecoxib against triple-negative breast cancer using zebrafish larval xenografts
Open the record for dataset details and reuse information.
Data from: NEK4 suppresses cell proliferation in BT20 triple-negative breast cancer cells by diminishing expression of cell cycle genes, while its depletion mitigates proliferation in other cell lines
Open the record for dataset details and reuse information.
Reshaping the landscape of locoregional treatments for breast cancer liver metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver
Open the record for dataset details and reuse information.
Prognostic Significance of Deep Learning-Based Tumor-Infiltrating Lymphocyte Assessment for Triple-Negative Breast Cancer
<p>The quantified manual and auto sTILs scores for the TNBC patiens from TCGA-BRCA cohort presented in the article "Prognostic Significance of Deep Learning-Based Tumor-Infiltrating Lymphocyte Assessment for Triple-Negative Breast Cancer" which is currently under review. </p>
Dataset of "Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer"
Open the record for dataset details and reuse information.
Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for triple negative breast cancer and gene set prediction combinations
<p>Supplementary data of manuscript <strong>'Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for triple negative breast cancer and gene set prediction combinations </strong><strong>Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for triple negative breast cancer and gene set prediction combinations'</strong></p>
Data for: Link between glucose metabolism and EMT drives triple negative breast cancer migratory heterogeneity
<p>Intracellular and environmental cues result in heterogeneous cancer cell populations with different metabolic and migratory behaviors. While glucose metabolism and EMT have previously been linked, we aim to understand how this relationship fuels cancer cell migration. We show that while glycolysis drives single-cell migration in confining microtracks, fast and slow cells display different migratory sensitivities to glycolysis and oxidative phosphorylation inhibition. Phenotypic sorting of highly and weakly migratory subpopulations (MDA<sup>+</sup>, MDA<sup>-</sup>) reveals that more mesenchymal, highly migratory MDA<sup>+</sup> preferentially use glycolysis while more epithelial, weakly migratory MDA<sup>-</sup> utilize mitochondrial respiration. These phenotypes are plastic and MDA<sup>+</sup> can be made less glycolytic, mesenchymal, and migratory and MDA<sup>-</sup> can be made more glycolytic, mesenchymal, and migratory via modulation of glucose metabolism or EMT. These findings reveal an intrinsic link between EMT and glucose metabolism that controls migration. Identifying mechanisms fueling phenotypic heterogeneity is essential to develop targeted metastatic therapeutics.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.